Jordi Naval, new CEO of Biocat

The Biocat Board of Trustees, chaired by Catalan Minister of Health Alba Vergés, has named Jordi Naval the organization's new CEO. Naval joined Biocat this past February as Director of Strategy. He is now taking over the position that was left vacant a year ago by the previous CEO Albert Barberà, current Director General for Research and Innovation in Health for the Government of Catalonia.

Jordi Naval (Barcelona, 1969) has a degree in Pharmacy from the University of Barcelona (UB) and in Biochemistry from the Autonomous University of Barcelona (UAB). Over the past 18 years, he has helped launch several start-ups: Infociencia, Anaxomics, Enemce Pharma, Genocosmetics Lab and Aelix Therapeutics, a spin-off of the Hivacat consortium that is developing the first therapeutic HIV vaccine. He was director of the Bosch i Gimpera Foundation from 2015 to 2017, and president of the Fundació Escola d’Emprenedors from 2010 to 2017.

"It is a privilege for me to take over at the helm of Biocat, where we are working to transform the great scientific potential generated in the BioRegion of Catalonia into tangible solutions that have a positive impact on patients -highlights Jordi Naval, new CEO of Biocat-. Our goal is to take part in the next period of growth of the innovation ecosystem, and place Catalonia as worldwide innovation reference hub in health sciences”.